2023 annual financial data
First Tracks Biotherapeutics 2023 Operating cash flow
Direct answer
Operating cash flow was -93,004,000 USD.
Operating income was -118,461,000 USD and net income was -106,150,000 USD.
Operating cash flow was -93,004,000 USD.
Get free First Tracks Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -118,461,000 USD
- Net income
- -106,150,000 USD
- Operating cash flow
- -93,004,000 USD